Hypothesis

Aging‑induced organ‑specific endothelial senescence releases extracellular vesicles (sEVs) that carry p53‑upregulated ultra‑large VWF multimers and the microRNA miR‑21. These sEVs disseminate a prothrombotic signal to distant endothelium, where miR‑21 suppresses thrombomodulin and endothelial protein C receptor (EPCR) expression, thereby blunting protein C activation and amplifying thrombin generation. This mechanism explains the coordinated rise in FVIII/VWF and the concurrent decline in anticoagulant capacity observed with age.

Rationale

• Endothelial senescence in brain, lung, and liver microvasculature increases p53 activity, driving VWF synthesis and secretion of high‑molecular‑weight (HM‑VWF) multimers [[https://www.ahajournals.org/doi/10.1161/ATVBAHA.123.319255]].
• Senescent cells are known to shed EVs enriched in specific RNAs and proteins that can alter recipient cell phenotype [[https://pubmed.ncbi.nlm.nih.gov/33221577/]].
• miR‑21 is upregulated in senescent endothelium and directly targets thrombomodulin (THBD) and EPCR (PROCR) mRNA, reducing APC generation [[https://pmc.ncbi.nlm.nih.gov/articles/PMC4338937/]].
• Declining protein C activation exacerbates the prothrombotic shift caused by elevated FVIII/VWF [[https://pmc.ncbi.nlm.nih.gov/articles/PMC12577834/]].

Predictions

1. Plasma levels of sEVs bearing VWF‑HM‑multimers and miR‑21 will increase linearly with age (≥40 y) and correlate with thrombin generation potential (ETP) and inversely with APC activity.
2. Individuals with non‑O blood groups will show higher sEV‑associated VWF burden, but the age‑related rise will be similar across genotypes after adjusting for inflammatory markers.
3. Pharmacologic inhibition of EV release (e.g., GW4869) or selective senolytic clearance (e.g., dasatinib + quercetin) in aged mice will reduce circulating sEV‑VWF/miR‑21, restore thrombomodulin/EPCR expression, lower thrombin generation, and decrease thrombosis incidence without increasing bleeding time.
4. Transfer of sEVs from old to young mice will recapitulate the prothrombotic phenotype (↑ETP, ↓APC) and this effect will be abrogated by anti‑miR‑21 oligonucleotides.

Experimental Design

Human cohort: Recruit 120 participants stratified by age (20‑30, 40‑50, 60‑70, 80‑90 y) and blood group (O vs non‑O). Collect plasma, isolate sEVs (ultracentrifugation), quantify VWF‑HM‑multimers (ELISA under non‑reducing conditions), miR‑21 (qPCR), thrombin generation (calibrated automated thrombogram), and APC activity (chromogenic assay). Perform multivariable regression to test age‑ and blood‑group‑adjusted associations.

Mouse model: Use 24‑month‑old C57BL/6 mice. Groups: (1) vehicle, (2) GW4869 (EV release inhibitor), (3) dasatinib + quercetin (senolytic), (4) GW4869 + anti‑miR‑21. Measure plasma sEV‑VWF/miR‑21, aortic thrombomodulin/EPCR (Western blot), thrombin generation, APC activity, and induced thrombosis (FeCl3 carotid injury) and bleeding (tail‑bleed time).

Gain‑of‑function: Isolate sEVs from old mice, inject into young (3‑month) recipients ± anti‑miR‑21. Assess same endpoints 24 h post‑injection.

Potential Outcomes & Interpretation

• Confirmation of predictions would establish sEV‑mediated transfer of senescence‑driven prothrombotic cargo as a unifying mechanism linking elevated FVIII/VWF and impaired protein C activation.
• Failure to observe age‑dependent sEV changes or lack of therapeutic effect would falsify the hypothesis, suggesting that other pathways dominate the age‑related coagulopathy.
• Demonstrating rescue by senolytics or EV inhibition would offer a translational avenue to rebalance coagulation in frail elderly, addressing the current dilemma of thrombosis‑vs‑bleeding risk.

Broader Implications

This hypothesis shifts focus from systemic factor concentrations to intercellular communication via senescent endothelial EVs. It suggests that biomarkers of endothelial senescence (e.g., CD62E⁺/Annexin V⁺ EVs) combined with miR‑21 profiling could refine thrombosis risk prediction, especially in under‑studied, resource‑limited populations where global coagulation assays are unavailable.